To determine the contribution of tumor cell-derived CCL2 to myoblast and myotube activity, CCL2 was knocked down by siRNA or shRNA in 4T1 cells, resulting in a respective 47% and 70% reduction (Fig. 2A; Fig. S4A). The gene discussed is CCL2; the disease is neoplasm.